Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells

  • Authors:
    • Toshiyuki Nanbu
    • Naoki Umemura
    • Emika Ohkoshi
    • Kumi Nanbu
    • Hiroshi Sakagami
    • Jun Shimada
  • View Affiliations

  • Published online on: November 21, 2017     https://doi.org/10.3892/or.2017.6105
  • Pages:367-375
Metrics: HTML 0 views | PDF 0 views
0

Abstract

The aim of the present study was to search for an effective regimen among existing chemotherapies for head and neck squamous cell carcinoma (HNSCC). Among the tested drugs, we focused on combined SN-38, which is the active metabolite produced from irinotecan hydrochloride - a type I DNA topoisomerase inhibitor - after it is metabolized by carboxylesterase in the liver and gefitinib, an EGFR tyrosine kinase inhibitor treatment, based on the ability of this combination to inhibit HNSCC cell growth. Contrary to our expectation, in vivo, there was no significant difference in tumor growth suppression between gefitinib-only treatment and gefitinib plus SN-38. However, when tumor measurements were continued after treatment ceased, we found that several tumors showed renewed growth in the gefitinib-only group. The tumors that resumed growing after treatment showed increased CD44 expression compared with tumors from the combined treatment group. Next, we investigated the mechanism whereby SN-38 and gefitinib inhibited CD44 expression in vitro. These studies revealed that the combined treatment promoted lysosomal degradation of CD44. The present study revealed that combined gefitinib and SN-38 treatment inhibits CD44 expression by promoting its lysosomal degradation in HNSCC cells. However, it is still unclear whether inhibition of CD44 expression in HNSCC cells can directly suppress tumor regrowth after therapy. Thus, it may be necessary to elucidate the relationship between the effects of these chemotherapeutic agents on CD44 expression and tumor recurrence/metastasis in future studies.

Related Articles

Journal Cover

January 2018
Volume 39 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

2016 Impact Factor: 2.662
Ranked #31/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nanbu, T., Umemura, N., Ohkoshi, E., Nanbu, K., Sakagami, H., & Shimada, J. (2018). Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells. Oncology Reports, 39, 367-375. https://doi.org/10.3892/or.2017.6105
MLA
Nanbu, T., Umemura, N., Ohkoshi, E., Nanbu, K., Sakagami, H., Shimada, J."Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells". Oncology Reports 39.1 (2018): 367-375.
Chicago
Nanbu, T., Umemura, N., Ohkoshi, E., Nanbu, K., Sakagami, H., Shimada, J."Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells". Oncology Reports 39, no. 1 (2018): 367-375. https://doi.org/10.3892/or.2017.6105